Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT-RT
NCT04513717Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jan 2021
- Primary completion
- Dec 2033
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by NRG Oncology. Started Jan 2021; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04513717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513717.